セマグルチドの市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

2型糖尿病の治療薬として承認されているセマグルチドは、肝線維症を悪化させることなくNASHの改善の可能性を高めたことが、AASLDバーチャル肝臓学会議で研究者らにより報告されました。セマグルチドとその他の2つの薬剤（firsocostatとcilofexor）を併用することで、線維化、代謝、肝臓の健康状態のさまざまな指標が大きく改善しました。NAFLD/NASHの発症には複数の生物学的プロセスが関与していることから、多くの専門家は、最適な治療には作用機序の異なる薬剤を組み合わせる必要があると考えています。

セマグルチドはGLP-1受容体作動薬で、インスリン分泌を増加させ、食欲調節や糖と脂質の代謝に関与する天然のGLP-1の作用を模倣します。Firsocostat（GS-0976）はアセチルCoAカルボキシラーゼ（ACC）阻害薬であり、ACCは肝臓における脂肪生成、すなわち糖質から脂肪酸への変換に関与します。Cilofexor（GS-9674）は非ステロイド性FXRアゴニストであり、FXRは胆汁酸合成を制御し、脂質と糖の代謝に関与しています。

当レポートでは、主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）における非アルコール性脂肪性肝炎（NASH）向けセマグルチドについて調査分析し、市場規模の予測や、作用機序、用法と用量、研究開発活動などの情報を提供しています。

目次

第1章 レポートのイントロダクション

第2章 非アルコール性脂肪肝炎（NASH）におけるセマグルチドの概要

• 製品詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期段階の新治療法）

第5章 セマグルチド市場の評価

• 非アルコール性脂肪肝炎（NASH）におけるセマグルチドの市場見通し
• 主要7市場の分析
  • 主要7市場の非アルコール性脂肪肝炎（NASH）向けセマグルチドの市場規模
• 各国の市場の分析
  • 米国の非アルコール性脂肪肝炎（NASH）向けセマグルチドの市場規模
  • ドイツの非アルコール性脂肪肝炎（NASH）向けセマグルチドの市場規模
  • 英国の非アルコール性脂肪肝炎（NASH）向けセマグルチドの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Semaglutide, Clinical Trial Description, 2023
• Table 2: Semaglutide, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Semaglutide Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Semaglutide Market Size in the US, in USD million (2019-2032)
• Table 7: Semaglutide Market Size in Germany, in USD million (2019-2032)
• Table 8: Semaglutide Market Size in France, in USD million (2019-2032)
• Table 9: Semaglutide Market Size in Italy, in USD million (2019-2032)
• Table 10: Semaglutide Market Size in Spain, in USD million (2019-2032)
• Table 11: Semaglutide Market Size in the UK, in USD million (2019-2032)
• Table 12: Semaglutide Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Semaglutide Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Semaglutide Market Size in the United States, USD million (2019-2032)
• Figure 3: Semaglutide Market Size in Germany, USD million (2019-2032)
• Figure 4: Semaglutide Market Size in France, USD million (2019-2032)
• Figure 5: Semaglutide Market Size in Italy, USD million (2019-2032)
• Figure 6: Semaglutide Market Size in Spain, USD million (2019-2032)
• Figure 7: Semaglutide Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Semaglutide Market Size in Japan, USD million (2019-2032)

"Semaglutide Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Semaglutide for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Semaglutide for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Semaglutide for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Semaglutide market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in NASH without worsening liver fibrosis, researchers reported at the AASLD virtual liver meeting. Combining semaglutide with two other drugs - firsocostat and cilofexor - led to greater improvements in various measures of fibrosis, metabolism, and liver health. Given the multiple biological processes that play a role in the development of NAFLD/NASH, many experts think optimal treatment may require combining drugs with different mechanisms of action.

Semaglutide is a GLP-1 receptor agonist that mimics the action of natural GLP-1, which increases insulin secretion and plays a role in appetite regulation and glucose and lipid metabolism. Firsocostat (GS-0976) is an acetyl-CoA carboxylase (ACC) inhibitor; ACC is involved in lipogenesis or conversion of carbohydrates to fatty acids in the liver. Cilofexor (GS-9674) is a nonsteroidal FXR agonist; FXR regulates bile acid synthesis and plays a role in lipid and glucose metabolism.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Semaglutide description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Semaglutide regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Semaglutide research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Semaglutide.
• The report contains forecasted sales of Semaglutide for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Semaglutide in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Semaglutide Analytical Perspective by DelveInsight

• In-depth Semaglutide Market Assessment

This report provides a detailed market assessment of Semaglutide for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• Semaglutide Clinical Assessment

The report provides the clinical trials information of Semaglutide for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Semaglutide dominance.
• Other emerging products for NASH are expected to give tough market competition to Semaglutide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Semaglutide in NASH.
• Our in-depth analysis of the forecasted sales data of Semaglutide from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Semaglutide in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Semaglutide?
• What is the clinical trial status of the study related to Semaglutide in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Semaglutide development?
• What are the key designations that have been granted to Semaglutide for NASH?
• What is the forecasted market scenario of Semaglutide for NASH?
• What are the forecasted sales of Semaglutide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Semaglutide for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. Semaglutide Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Semaglutide Market Assessment

• 5.1. Market Outlook of Semaglutide in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Semaglutide in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Semaglutide in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of Semaglutide in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of Semaglutide in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of Semaglutide in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of Semaglutide in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of Semaglutide in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of Semaglutide in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options